DARE-trial: A Trial Studying the Effect of the SeQuent Please Drug-eluting Balloon Compared to the Xience Prime Drug-eluting Stent for the Treatment of Stenosis of an Earlier Implanted Stent.

In-stent Restenosis Clinical Trial

Official title:
DARE-Trial: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomized Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the Xience Prime Drug-eluting Stent for the Treatment of In-stent Restenosis.

Status Active, not recruiting

Clinical Trial Summary

The main objective of the study is to determine whether PCI for in-stent restenosis with a drug eluting balloon is angiographically non-inferior to PCI with a drug eluting stent at 6 month follow up.

Clinical Trial Description

Background of the study:

Coronary in-stent restenosis is commonly treated by using a drug eluting stent (DES). There are, however, some concerns about the safety of drug eluting stents, in particular with respect to delayed healing, chronic inflammatory reaction, and late or very late stent thrombosis. It is unknown whether the current treatment with another layer of stents may add to the risk of stent thrombosis or reoccurrence of restenosis. Therefore, the relatively new drug-eluting balloons may provide an alternative for treatment of in-stent restenosis, avoiding a double stent layer. The expected advantages of such drug-eluting balloons over stents are the ease of access of the lesion, the absence of a multiple stent layer, and the shorter necessity of the use of dual antiplatelet therapy. Several studies have demonstrated safety and efficacy of the Sequent Please drug-eluting balloon (DEB). Whether the drug eluting balloon is as effective as a drug eluting stent in preventing re-restenosis is not known.

Study design:

The study is designed as an multi-center, randomized, prospective two-arm trial with either PCI with a drug eluting balloon or a drug eluting stent for in-stent restenosis. Blinded evaluation of endpoints by independent core laboratory.

Study population:

The study population consists of 270 patients ( ≥ 18 years of age) with indication for PCI for in-stent restenosis of whom 135 are randomised to a drug eluting balloon and 135 are randomised to a drug eluting stent. Individuals have signed an informed consent for study measurements.

Intervention:

PCI with a drug-eluting stent, or PCI with a drug-eluting balloon. ;

Study Design

Related Conditions & MeSH terms

In-stent Restenosis

Clinical Trial Details

NCT number	NCT01127958
Study type	Interventional
Source	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact
Status	Active, not recruiting
Phase	N/A
Start date	May 2010
Completion date	June 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00341562` - Genomics of In-Stent Restenosis	N/A
Completed	`NCT05509296` - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease	N/A
Not yet recruiting	`NCT06090890` - Anti-inflammatory Therapy for Recurrent In-stent Restenosis	Phase 4
Active, not recruiting	`NCT00998439` - Treatment of Drug-eluting Stent (DES) In-Stent Restenosis With SeQuent® Please Paclitaxel Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheter	Phase 2
Active, not recruiting	`NCT05731700` - CVT-ISR First in Human Trial for Coronary In-Stent Restenosis	N/A
Completed	`NCT03260517` - The PREVAIL Study	N/A
Not yet recruiting	`NCT03588962` - Metal Allergy In-Stent Restenosis Study	N/A
Completed	`NCT00393315` - P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses	Phase 2
Recruiting	`NCT03874481` - The Effect of Sleep Quality on Coronary Artery Disease and In Stent Restenosis
Active, not recruiting	`NCT04647253` - A Clinical Trial to Assess the Agent Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects With In-Stent Restenosis (ISR)	Phase 3
Active, not recruiting	`NCT03529006` - Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis	N/A
Completed	`NCT00485030` - Diffuse Type In-Stent Restenosis After Drug-Eluting Stent	Phase 4
Not yet recruiting	`NCT03809754` - Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis	N/A
Completed	`NCT00916279` - PERVIDEO I Registry, The Lutonix Paclitaxel-Coated Balloon Catheter for the Treatment of Coronary In-Stent Restenosis	Phase 1/Phase 2
Recruiting	`NCT05473884` - Lesion Preparation in Femoropopliteal Artery Occlusion Disease
Recruiting	`NCT01239940` - RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)	Phase 4
Active, not recruiting	`NCT01239953` - RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)	Phase 4
Not yet recruiting	`NCT06148441` - Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention
Completed	`NCT05512832` - In-stent Restenosis and Pericoronary Fat Attenuation Index
Recruiting	`NCT03521843` - LDD in Treatment of Femoropopliteal ISR	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.